Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT – UPDATE ON A GRANISETRON TRANSDERMAL PATCH PRODUCT

The Board of the Company is pleased to announce that, on 24th July 2018, Sancuso® (Granisetron Transdermal System) which the Group obtained its exclusive license rights for commercialisation and promotion in China (excluding Beijing, Shanghai and Guangzhou) from Solasia Pharma K.K. (Solasia) in 2015, has been approval for launch by the China National Drug Administration ("CNDA").

Sancuso® is the world's first and only transdermal patch of the 5-HT3 receptor antagonist used for the prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy regimens. It provides chemotherapy patients with a persistently effective new noninvasive drug delivery system for the prevention of nausea and vomiting. Sancuso® will further enhance our Group's position to offer patients a comprehensive treatment solution in the oncology space.

The chemotherapy-induced nausea and vomiting (CINV) is one of the most common and most painful adverse reactions during the chemotherapy process of cancer patients. According to statistics, without any anti-emetic measures, 70%-80% of chemotherapy patients would experience CINV (Wiser and Berger, Oncology (Williston Park) 2005). CINV lowers patients' quality of life, causes metabolic disorders, malnutrition, weight reduction and fear for chemotherapy, and reduces their treatment compliance. In severe cases, patients will have to be treated with reduced dosage or even withdrawn from chemotherapy, with negative impacts on the treatment outcomes (Guidelines for management of cancer treatment related vomiting, 2014 edition). Therefore, authoritative guidelines including the National Comprehensive Cancer Network (NCCN) guidelines have made clear that standard and whole process CINV management must be taken for patients receiving moderately and/or highly emetogenic chemotherapy (Antiemesis 2017, version 2).

The newly-approved 5-HT3 receptor antagonist transdermal system features a skeletal structure and is originated by ProStrakan Inc., US. The patch can be attached by patients to the outer side of their arm. Depending on different chemotherapy courses, it can be used for up to 7 days and can meet the needs of patients with anticipatory nausea and vomiting or acute/delayed nausea and vomiting in different stages. Data from the clinical studies for registration purpose in some European countries and the United States as well as in China shows that Granisetron transdermal system has a more stable blood concentration (Howell et al, J Oncol Pharm Pract 2009) and similar safety profile with well tolerance compared to oral intake. Professor Qin Shukui, the deputy director of Hospital of People's Liberation Army of China/the vice chairman of CSCO (Chinese Society of Clinical Oncology)/the chairman of CRPC (The committee of Rehabilitation and Palliative Care)/the chairman of PLA Cancer Center & China Drug Clinical Trial Institution, said: "The whole process management of CINV before and after chemotherapy is the standard practice recommended by all major guidelines. The NCCN guidelines made clear that, after the last dose of chemotherapy, the emetic risk will last for at least 2-3 days for patients receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) respectively, so active protection is still needed. But it is very difficult to follow the recommendation in China's clinical practice, especially for delayed CINV. In our country, 95% of the CINV drugs are injections, so it's very difficult to maintain CINV prevention once the patients leave hospital. Delayed nausea and vomiting of patients outside of hospital has become a blind zone. With the successful approval of Granisetron transdermal system, its 7-day stable efficacy makes the whole process CINV management possible, especially after discharging from hospital. This has greatly enhanced the treatment compliance and convenience. It can effectively help patients keep receiving chemotherapy and improve their quality of life."

As the only 5-HT3 receptor antagonist transdermal system, Sancuso® was first approved for launch in the U.S. in 2008. Since 2011, the NCCN/American Society of Clinical Oncology (ASCO) (Basch et al, J Clin Oncol 2011) have recommended Sancuso® in their antiemetic guidelines. In 2014, the antiemetic guidelines of the Multinational Association of Supportive Care in Cancer (MASCC)/European Society for Medical Oncology (ESMO) as well as China's antiemetic guidelines also recommended the use of Sancuso®.

Sancuso® is the Granisetron transdermal system used for the prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy regimens. Each 52cm^2 patch contains 34.3mg of Granisetron and releases 3.1mg of Granisetron every 24 hours for up to 7 days. Granisetron transdermal system is a persistently effective noninvasive drug delivery system with a proven safety profile (Boccia et al, Support Care Cancer 2011 & Kim et al, Support Care Cancer 2015). To date, Sancuso® has been launched in 22 countries and regions including the United States, UK, Germany, the Netherlands, and Denmark. In 2014, a clinic pharmacology study as well as a random and double-blind clinical study versus oral Granisetron was completed in China (Yang et al Chin Clin Oncol 2016). In July 2018, it was finally approved by the CNDA.

Solasia is an Asia-based pharmaceutical company dedicated to developing and selling innovative cancer treatment supportive drugs for local markets. As to benefit patients in China, the company is focused on creating a cancer treatment system in Asia, by developing innovative cancer drugs, introducing and getting commercial development licenses for great products from leading pharmaceutical and biotech companies in Japan, Europe and U.S.A, and other Asian countries. Solasia actively responds to the needs of patients and healthcare professionals and works hard to improve patient's life and meet the key unmet needs in oncology. For more information about the company, please visit www.solasia.co.jp/en/

The Group is fully integrated with solid infrastructures in drug development, clinic, perspectives and the Group has established extensive partnerships with over 20 international companies and currently markets 17 proprietary and licensed-in pharmaceutical products in Mainland China, Hong Kong and Macau. The Group focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology, ophthalmology and others. The Group has more than 50 products under different development stages stemming from both internal research and development as well as from the recent acquisition of licensing and distribution rights from various United States, European and Japanese companies. For more information about the company, please visit www.leespharm.com

By order of the Board of
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 16 August 2018

* *For identification purpose only*

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive directors of the Company, Mr. Simon Miles Ball is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.